Crinetics Pharmaceuticals is set for a fall 2025 launch of paltusotine, with strong Wall Street support despite being ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

a less useful outcome-based KPI for pharma than for other industries." High performing sales organisations operationalise their call coverage models off a clearly defined plan that begins with ...

This is particularly true when it comes to technology and the current systems that most pharmaceutical companies deploy. Traditional sales software has been essentially a call reporting and ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Lifecore Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Good ...

Vanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt ... investors on the latest earnings call to expect lower margins on some ...

If 2023 was a year of wonder about artificial intelligence, 2024 was the year to try to get that wonder to do something ...

During a panel debate, MEPs from EPP, S&D, Renew, and Greens agreed that the pharma package ... it is the peak year sales you remove," he added. The panel of MEPs pointed out that with sufficient ...